TEST:

Ion AmpliSeq Colon and Lung Cancer Research Panel v2

We demonstrated the accuracy and potential clinical utility of the Idylla EGFR Mutation Test as a molecular screening platform in terms of turnaround time and molecular testing cost if applied to a cohort with a high EGFR mutation incidence (>17.9%).

Volatile biopsy(EBC) is a new, easily reproducible, non-invasive method both molecular diagnosis and follow-up of LA. Acknowledgement: We thank TUBITAK(216S435) and Presidency of Turkey, Presidency of Strategy and Budget(2019K12-149080) for their grant supports.

This exploratory analysis suggests that patients with any tumour mutation in MAPK pathway genes are not good candidates for maintenance treatment with cetuximab or treatment interruption after first-line FOLFIRI-cetuximab.